Crossfire Oncology

Jos de Man, Head of Chemistry at Crossfire Oncology will give an oral presentation on CFON-026, a macrocycle that disrupts the BTK protein scaffold thereby inhibiting all clinically relevant BTK resistance mutations, at the upcoming AACR Annual Meeting 2025 on April 28 in Chicago, Illinois. Don’t miss the chance to listen to the discovery of this amazing EPriL-derived non-covalent BTK inhibitor and its outstanding pharmacology resulting in pan-mutant BTK inhibition. Date: April 28 Time: 2.30 – 4.45 PM Location: Room S103 – McCormick Place South (Level 1) Presentation title: CFON-026 is a macrocycle that disrupts the BTK protein scaffold thereby inhibiting all clinically relevant BTK resistance mutations Session: Minisymposium on Novel Antitumor Agents   The Crossfire Team, represented by Joost Uitdehaag, Head of Biology, will also present a poster on their Degrader-Antibody Conjugate platform. April 29, 2-5 PM, poster 5468, section 15, board 26.

Only two more days and then the NextGen Biomed conference will start in London! Our Head of Biology Joost Uitdehaag will give a talk on 14-Mar at noon titled "A rationally designed cell cycle kinase degrader as a novel payload of ADCs". Winfried Mulder will be presenting a poster with the same title but providing more details on our sophisticated DAC technology. Interested in learning more about how we target cancer cells that are R/R to classical payloads? Make sure you meet with Joost and/or Winfried while in London.

Tomorrow our Head of Biology Joost Uitdehaag will present the latest on our innovative Degrader Antibody Conjugate technology at the World ADC conference (Session 2, 5th March, 10:30 - 11:30am, Poster Number 18). He is looking forward to meet you!

Only one more week till the World ADC conference in London! Do come and visit our poster, where our Head of Biology Joost Uitdehaag will be presenting the most recent developments on our novel Degrader Antibody Conjugate technology, showing high potency of our DACs for several cancer indications.

3-6 March we will be attending the annual world ADC meeting in London! Our Head of Biology, Joost Uitdehaag, will present here the latest on our sophisticated cell cycle kinase degrader and its unique payload properties. So do visit him at the poster titled: "a rationally designed cell cycle kinase degrader as a novel payload for ADCs". See you in London! https://lnkd.in/eVkYdzm

Wednesday 6-Nov (11:45AM CET) Joost Uitdehaag will give an exciting presentation about Crossfire's novel DAC platform at #PEGSEurope. He will tell you about the cell cycle degrader payload that we designed with the patient in mind and how it ticks all the boxes for becoming a breakthrough innovation in the ADC field. We look forward to meeting with you all in Barcelona!

Only a few more days and we will be presenting two exciting posters at the EORTC-NCI-AACR (ENA) symposium in Barcelona! On 23 October Yvonne van Mil will be presenting "CFON-026, a best-in-class macrocyclic non-covalent inhibitor of BTK(WT) and all clinically relevant BTK resistance mutations" On 24 October Joost Uitdehaag will be presenting "A novel kinase degrader-based payload for the development of potent Degrader Antibody Conjugates (DACs)" We're looking forward to meeting with you all! https://lnkd.in/eb6tKDZE

This week Crossfire will be attending and presenting at the Dutch Medicines Days! Martine Prinsen will present a poster about our proprietary and highly potent Degrader Antibody Conjugate technology, which allows for the targeted treatment of cancer via a completely novel Mechanism of Action. Joost Uitdehaag will talk about CFON-026, our unique non-covalent BTK inhibitor, which has best-in-class properties for the treatment of hematological cancers like CLL, MCL and MZL. Looking forward to it! https://lnkd.in/eG4Zg54C

Yesterday the Marie Curie building at the Pivot Park in Oss was officially opened! Extremely proud, and happy, to be working in a building that is designed to bolster innovation!

We are honoured to be invited for an oral presentation at PEGS Europe! Joost Uitdehaag will elaborate on the sophisticated design of our highly innovative degrader-based payload and how it can overcome the challenges associated with classical payloads. Make sure to visit his talk: Beyond the Classical Payloads—Kinase Degraders as Antibody Armaments https://lnkd.in/ge4ZTX5